Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial

Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial

BackgroundNitazoxanide exerts antiviral activity in vitro and in vivo and anti-inflammatory effects, but its impact on patients hospitalized with COVID-19 pneumonia is uncertain.MethodsA multicentre, randomized, double-blind, placebo-controlled trial was conducted in 19 hospitals in Brazil. Hospital...

Full description

Bibliographic Details
Main Authors: Patricia R. M. Rocco, Pedro L. Silva, Fernanda F. Cruz, Paulo F. G. M. M. Tierno, Eucir Rabello, Jéfiton Cordeiro Junior, Firmino Haag, Renata E. de Ávila, Joana D. G. da Silva, Mariana M. S. Mamede, Konrad S. Buchele, Luiz C. V. Barbosa, Anna C. Cabral, Antônio A. F. Junqueira, João A. Araújo-Filho, Lucianna A. T. J. da Costa, Pedro P. M. Alvarenga, Alexandre S. Moura, Ricardo Carajeleascow, Mirella C. de Oliveira, Roberta G. F. Silva, Cynthia R. P. Soares, Ana Paula S. M. Fernandes, Flavio Guimarães Fonseca, Vidyleison Neves Camargos, Julia de Souza Reis, Kleber G. Franchini, Ronir R. Luiz, Sirlei Morais, Carlos Sverdloff, Camila Marinelli Martins, Nathane S. Felix, Paula Mattos-Silva, Caroline M. B. Nogueira, Dayene A. F. Caldeira, Paolo Pelosi, José R. Lapa-e-Silva
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Medicine
Subjects:
D-dimer
oxygenation
pneumonia
SARS-CoV-2
COVID-19
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.844728/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.844728/full

Similar Items